Investigation Launched Into Immunovant's Private Placement Transaction: What Investors Should Know

Investigation Launched into Immunovant's Private Placement Transaction

On May 29, 2025, Robbins Geller Rudman & Dowd LLP announced an investigation focusing on potential breaches of fiduciary duty by the directors and officers at Immunovant, Inc. (NASDAQ: IMVT) and its controlling stockholder, Roivant Sciences Ltd. This inquiry is particularly linked to a private placement transaction that took place in January 2025. During this transaction, Roivant acquired nearly 16.9 million shares of Immunovant at a price of $20.00 per share, significantly discounting the previous trading day's closing price by $3.48 per share.

Background of Immunovant

Immunovant is a clinical-stage immunology company that came into existence following a merger with Health Sciences Acquisitions Corporation (HSAC) in December 2019. Roivant, which has maintained control over a majority of Immunovant's shares—between 54.6% and 73.8% since the merger—has been at the center of this investigation. The recent actions have raised concerns among investors regarding the directors' responsibilities and the integrity of their decision-making processes.

Details of the Private Placement Transaction

The share purchase agreement disclosed on January 13, 2025, informs that Immunovant sold 16,845,010 shares through a private placement to Roivant for $20.00 per share. Intriguingly, this share price reflects a discount that had not been seen since August 2023, almost 18 months prior. With the discrepancy of $3.48 per share constituting a financial boon for Roivant, the company's shareholders are understandably alarmed. This equates to a staggering benefit of nearly $60 million favoring Roivant at the possible cost of Immunovant’s existing investors.

Call to Action for Investors

Investors currently holding Immunovant shares are urged to stay informed regarding the unfolding investigation. Robbins Geller encourages affected parties to engage with their legal team to discuss potential actions that could be taken to protect their investments. Further details can be acquired by providing information on the following link: Robbins Geller's Immunovant Investigation Page.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the leading law firms specializing in complex class action suits, especially those involving mergers and securities fraud. The firm has garnered a strong reputation, securing the most monetary relief for investors in the last five years, showcasing its commitment to client advocacy. In 2024 alone, Robbins Geller achieved over $2.5 billion in recoveries from securities-related class action cases, marking it as a notable player within the legal landscape. For more information about their services and recent successes, you can visit Robbins Geller's Website.

Final Thoughts

As the investigation progresses, investors and stakeholders are advised to remain vigilant and proactive in seeking information related to their investments in Immunovant. This unfolding situation exemplifies the intricate interplay between corporate governance, investor rights, and legal oversight, which can significantly impact the market landscape and investor portfolios. By staying engaged and informed, investors can better navigate these challenging waters and advocate for their rights as stakeholders.